Valeant Pharmaceuticals International's (VRX) "Hold" Rating Reiterated at HC Wainwright

Valeant Pharmaceuticals International's (VRX)

Cantor Fitzgerald initiated Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, June 16 with "Overweight" rating. (NYSE:VRX) (TSE:VRX) in a report issued on Friday morning.

The company has been rebuilding its business after coming under fire for its steep drug price hikes and the unorthodox use of a specialty pharmacy to boost sales.

Other equities analysts have also issued reports about the stock. Piper Jaffray Companies set a $14.00 target price on Valeant Pharmaceuticals International and gave the stock a "sell" rating in a research note on Sunday, October 22nd. The stock has "Buy" rating by Jefferies on Monday, December 7. Finally, Morgan Stanley set a $42.00 target price on Valeant Pharmaceuticals International and gave the company a "buy" rating in a research report on Tuesday, November 8th. Finally, Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a strong sell rating to a hold rating in a research report on Thursday, July 27th.

Among 5 analysts covering Advanced Accelerator (NASDAQ:AAAP), 2 have Buy rating, 0 Sell and 3 Hold. The company has an average rating of "Hold" and a consensus price target of $39.63. (NYSE:VRX) shares are seeing unusual volume mid-trading session today. The company has market cap of $5.12 billion. The company has a debt-to-equity ratio of 6.86, a quick ratio of 1.10 and a current ratio of 1.34. (VRX, VRX.TO) updated its full-year revenue guidance in the range of $8.65 - $8.80 billion from a prior range of $8.70 - $8.90 billion.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Investorplace.com which released: "The Lesson of Enterprise Value for Valeant Pharmaceuticals Intl Inc" on October 23, 2017, also Seekingalpha.com with their article: "Valeant: Uceris Patent Loss Could Further Impair Salix" published on November 03, 2017, Benzinga.com published: "Valeant Surrenders Some Early Gains After FDA Approval Of VYZULTA" on November 03, 2017. After $1.05 actual earnings per share reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -8.57% negative EPS growth.

Third-quarter total revenues were $2.22 billion, compared to $2.48 billion in the third quarter of 2016, a decrease of 10%. The SI to Valeant Pharmaceuticals Internat's float is 11.5%. Valeant Pharmaceuticals International's revenue for the quarter was down 7.7% compared to the same quarter last year. analysts anticipate that Valeant Pharmaceuticals International will post 3.68 EPS for the current year.

MONTREAL _ Valeant Pharmaceuticals International Inc. has signed a deal to sell its Sprout Pharmaceuticals subsidiary and its female sexual dysfunction drug to the company's former owners. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright laws. The stock was acquired at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Goldman Sachs Gp owns 0.02% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 4.60M shares. Institutional investors and hedge funds own 49.74% of the company's stock. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company's stock worth $1,622,000 after purchasing an additional 295 shares during the last quarter. LPL Financial LLC boosted its stake in Valeant Pharmaceuticals International by 65.5% in the first quarter. Oakmont Corp owns 517,560 shares or 7.61% of their U.S. portfolio. Tiaa Cref Inv Mgmt Limited Liability Corp invested 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). NEXT Financial Group Inc increased its holdings in Valeant Pharmaceuticals International by 6.2% in the second quarter.

Related:

Comments

Latest news

Meryl Streep clarifies 1979 groping allegation against Dustin Hoffman
Hoffman also reportedly taunted Streep about actor John Cazale, her boyfriend who died of lung cancer while they were dating. Streep's representative added, "There was an offense and it is something for which Dustin apologized".

LiAngelo Ball Arrested In China for Shoplifting ... UCLA Cooperating with Officials
The team is set to open its regular season against Georgia Tech in Shanghai on Friday. There is now a non-zero chance that LaVar Ball will start an global incident.

Small plane goes down in Gulf of Mexico in Pasco County
The spokesperson for the Sheriff's office said the National Transportation Safety Board will be leading the investigation. An airplane with the tail number registered to Halladay crashed into the Gulf north of Bailey's Bluff in Holiday, Fla .

Big tech tie-up: Broadcom bids $130 billion for Qualcomm
According to recent reports, Broadcom has been making a bid for Qualcomm last Monday and the amount is a staggering $103 billion. Broadcom, meanwhile, is seeking to buy United States rival Brocade Communications in a deal being reviewed by Washington.

Lockdown lifted at USC Upstate as police search for shooting suspect
Whaley said students were being told to stay inside buildings and lock their doors as the suspect was still at large and on foot. The University of South Carolina Upstate campus is in a lockdown for all its facilities, according to campus police.

Other news